34 results
6-K
EX-99.1
SLN
Silence Therapeutics Plc
29 Apr 24
Silence Therapeutics Announces Retirement of Alistair Gray from Board of Directors
8:36am
(Nasdaq: SLN) (“Silence” or the “Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing … of RNA interference, developed a pipeline of innovative product candidates, secured meaningful big pharma partnerships and established a first-class
6-K
EX-99.1
SLN
Silence Therapeutics Plc
13 Mar 24
Current report (foreign)
7:10am
”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines
6-K
EX-99.1
SLN
Silence Therapeutics Plc
23 Feb 24
Silence Therapeutics Achieves $10 Million Milestone Payment from AstraZeneca
8:12am
23 February 2024
LONDON, Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company … programs and develop the next wave of innovative therapies that address cardiovascular, renal and metabolic diseases,” said Regina Fritsche Danielson, SVP
6-K
EX-99.3
SLN
Silence Therapeutics Plc
6 Feb 24
Securities Purchase Agreement
12:00am
(Nasdaq: SLN) (“Silence” or the “Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing
6-K
EX-99.1
an7ryxcn 3n
1 Dec 23
Silence Therapeutics Strengthens Executive Leadership Team with Key Appointments
7:00am
6-K
EX-99.1
w6nbi2kcjlqzz4i4f1h
1 Nov 23
Current report (foreign)
7:00am
6-K
EX-99.1
ny0cg aarkzio324mu5x
11 Jul 23
Silence Therapeutics Achieves $4 Million in Research Milestone Payments from Hansoh Pharma Collaboration
7:00am
6-K
EX-99.1
dwkdr6
4 May 23
Silence Therapeutics Achieves $10 Million Milestone Payment from AstraZeneca Collaboration
7:41am
6-K
EX-99.1
181kwg4bj400x012a
1 May 23
Current report (foreign)
7:31am
6-K
EX-99.1
vx5tfdp
7 Nov 22
Assessment showed participants who received a single dose of SLN360 maintained median reductions over 80% over a five-month period
8:30am
6-K
EX-99.2
aii38x73jdkzsu
15 Oct 21
Notice of General Meeting to be held on 1 November 2021
7:15am
20-F/A
qde9l r0xxqz
29 Apr 21
Annual report (foreign) (amended)
4:26pm
424B4
09s f6rdo
12 Apr 21
Prospectus supplement with pricing info
11:12am
424B4
i9db9
12 Apr 21
Prospectus supplement with pricing info
11:11am
POS AM
02chkvmgl mvo0
8 Apr 21
Prospectus update (post-effective amendment)
9:31am
POS AM
f9eo477
8 Apr 21
Prospectus update (post-effective amendment)
9:18am
20-F
6h81jkmm
30 Mar 21
Annual report (foreign)
5:22pm